In November 2024, Trace launched with a mission to develop genomic medicines for neurodegenerative diseases, starting with #ALS. Thank you to our team members and the patients, caregivers, advocates, and partners who’ve been part of these first two years. Here’s to building on this progress together. We're confident there is a better future ahead for those affected by ALS.
Trace Neuroscience
Verified account This account is verified. Learn more@TraceNeuro
On a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases
16 Following 120 Followers 67 Posts
Latest posts 5
Great conversation at #Stifel2026! Our CEO @ercgrn joined @bradloncar on @BiotechTV to share insight into Trace’s mission to go after one of the most common drivers of ALS: the loss of UNC13A. Thanks to Brad and the Biotech TV team for having us. Watch the full interview below.
𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: @TraceNeuro believes that a breakthrough in ALS will be due to restoring expression of a protein called UNC13A, which most ALS patients don't have sufficient due to genetic factors.View quoted post on X
Full video: biotechtv.com/post/stifel-20…
Catch Trace leaders at two upcoming investor conferences this November!
CEO and co-founder @ercgrn will attend the @Stifel Healthcare Conference on Wednesday, November 11th in New York. Additionally, he’ll be joined by CBO @NMordwinkin at the @Jefferies Global Healthcare Conference November 16-19 in London.
We look forward to connecting with investors and industry peers at both. Reach out if you'd like to connect!
CEO and co-founder @ercgrn will attend the @Stifel Healthcare Conference on Wednesday, November 11th in New York. Additionally, he’ll be joined by CBO @NMordwinkin at the @Jefferies Global Healthcare Conference November 16-19 in London.
We look forward to connecting with investors and industry peers at both. Reach out if you'd like to connect!
Sanjay Chandriani is part of a @TargetALS_fdn-funded consortium investigating cryptic circular RNAs as biomarkers of TDP-43 dysfunction in #ALS. Better biomarkers mean getting the right therapy to the right person. Learn more about the $2.4M initiative. targetals.org/news/science-o…
At Trace, we're driven by a deeper understanding of the genetic drivers of ALS to make medicines for people with this disease. At the helm is CEO @ercgrn, who was honored as one of @GoldmanSachs most exceptional entrepreneurs at their Builders & Innovators Summit. Congrats, Eric!